ReviewNature reviews. Gastroenterology & hepatology2016
Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options.
Review in Nature reviews. Gastroenterology & hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 3 syntheses or guidelines pooled it, 159 citations in OpenAlex.
- Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection.The Journal of infectious diseases · 2020Pooled it
- Epidemiology of hepatitis B, C and D in Malawi: systematic review.BMC infectious diseases · 2018Pooled it
- Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review and meta-analysis.The Lancet. Global health · 2017Pooled it
- Absence of Detectable Anti-HDV Antibodies Among HBsAg-Positive Blood Donors, HIV-Infected Individuals and Patients With Chronic Hepatitis B in Sao Paulo, Brazil: Evaluation Using a Rapid Lateral Flow Assay.Journal of viral hepatitis · 2026Article
- Topological Stability and Transcritical Bifurcations in a Target-Cell-Limited Model of HBV-HDV Viral Interference.Viruses · 2026Article
- A replication-competent deltavirus from the marsupial fat-tailed dunnartThe Journal of general virology · 2026Article
- Multimodal characterization of the responsiveness of eight hepatitis D virus genotype isolates to interferon-alpha treatment.Journal of virology · 2025Article
- Article
- Host Immune Response in Chronic Hepatitis Delta: Implications for Pathogenesis and Therapy.Pathogens (Basel, Switzerland) · 2025Review
- Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D.Virology journal · 2025Review
- Impact of Universal Screening for HDV in HBV-Infected Patients on Chronic HDV Detection Rate in Israel.Journal of viral hepatitis · 2025Article
- Droplet Digital PCR: A Powerful Tool for Accurate Quantification of Hepatitis D Virus RNA Levels and Verification of Detection Limits.Journal of viral hepatitis · 2025Article
- Development of a dual channel detection system for pan-genotypic simultaneous quantification of hepatitis B and delta viruses.Emerging microbes & infections · 2024Article
- Acacetin, a Natural Flavone with Potential in Improving Liver Disease Based on Its Anti-Inflammation, Anti-Cancer, Anti-Infection and Other Effects.Molecules (Basel, Switzerland) · 2024Review
- Protective role of RIPK1 scaffolding against HDV-induced hepatocyte cell death and the significance of cytokines in mice.PLoS pathogens · 2024Article
- Hepatitis Delta Virus and Hepatocellular Carcinoma.Pathogens (Basel, Switzerland) · 2024Review
- The Culprit Behind HBV-Infected Hepatocytes: NTCP.Drug design, development and therapy · 2024Review
- [Delta hepatitis in Africa: epidemiological and clinical particularities].Medecine tropicale et sante internationale · 2023Review
- CRISPR/Cas13a-Assisted accurate and portable hepatitis D virus RNA detection.Emerging microbes & infections · 2023Article
- Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV/HDV.JHEP reports : innovation in hepatology · 2023Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hepatitis D is the most severe form of viral hepatitis, affecting ∼20 million HBV-infected people worldwide. The causative agent, hepatitis delta virus (HDV), is a unique human pathogen: it is the smallest known virus; it depends on HBV to disseminate its viroid-like RNA; it encodes only one protein (HDAg), which has both structural and regulatory functions; and it replicates using predominantly host proteins. The failure of HBV-specific nucleoside analogues to suppress the HBV helper function, and the limitations of experimental systems to study the HDV life cycle, have impeded the development of HDV-specific drugs. Thus, the only clinical regimen for HDV is IFNα, which shows some efficacy but long-term virological responses are rare. Insights into the receptor-mediated entry of HDV, and the observation that HDV assembly requires farnesyltransferase, have enabled novel therapeutic strategies to be developed. Interference with entry, for example through blockade of the HBV-HDV-specific receptor sodium/taurocholate cotransporting polypeptide NTCP by Myrcludex B, and inhibition of assembly by blockade of farnesyltransferase using lonafarnib or nucleic acid polymers such as REP 2139-Ca, have shown promising results in phase II studies. In this Review, we summarize our knowledge of HDV epidemiology, pathogenesis and molecular biology, with a particular emphasis on possible future developments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.